Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 3,400 shares, a growth of 30.8% from the January 15th total of 2,600 shares. Based on an average daily volume of 10,600 shares, the days-to-cover ratio is presently 0.3 days.
Genenta Science Stock Performance
GNTA traded up $0.13 on Thursday, reaching $3.93. The company had a trading volume of 390 shares, compared to its average volume of 8,991. The company has a fifty day moving average of $4.40 and a 200-day moving average of $4.59. Genenta Science has a one year low of $2.20 and a one year high of $7.28.
Institutional Trading of Genenta Science
An institutional investor recently bought a new position in Genenta Science stock. Citadel Advisors LLC bought a new position in Genenta Science S.p.A. (NASDAQ:GNTA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 11,167 shares of the company's stock, valued at approximately $46,000. Citadel Advisors LLC owned 0.06% of Genenta Science at the end of the most recent reporting period. 15.13% of the stock is currently owned by institutional investors.
About Genenta Science
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Read More
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
